Skip to main content

LINC 2020: Sirolimus-Coated Balloon is Safe FUTURE Alternative to Treat Peripheral Vascular Disease (Sponsored)

LINC 2020: Sirolimus-Coated Balloon is Safe FUTURE Alternative to Treat Peripheral Vascular Disease (Sponsored)

Dr. Sahil Parikh (USA) moderates a panel with Dr. Dierk Scheinert (Leipzig, Germany) and Prof. Edward Choke (Singapore) to discuss the next move to sirolimus-coated balloons from paclitaxel-coated balloons to treat peripheral vascular disease.

Dr. Choke discusses the safety and efficacy of sirolimus compared to paclitaxel in terms of treatment in peripheral vascular disease (PVD). He also explains Concept Medical’s new drug-eluting technology, which is beneficial to both patients and doctors.

Dr. Choke shares his experience with Magic Touch PTA and discusses promising results of the ongoing XTOSI study with the sirolimus-coated balloon. He adds that despite having significant 2 challenges in the trial: high-risk patients and almost exclusive critical limb ischemia (CLI) patients, overall patency at 6 months is 80%, which is very promising. Furthermore, he discusses the subset analysis of superficial femoral arteries (SFA) and below-the-knee (BTK) vessels with the XTOSI trial. The sirolimus-coated balloon showed 88% patency at 6 months in SFA group and 74% patency at 6 months in BTK group. Importantly, he shares his previous experience with paclitaxel-coated balloons (PCB) in the trial: patency with PCB was 40% in the BTK group compared to 74% patency in the sirolimus-coated balloon BTK group, which is highly promising.

Dierk Scheinert is convinced that the sirolimus-coated balloon and its technology is safe to treat PVD. He adds that the sirolimus-coated balloon is an unmet need for the next generation and an improved version of drug-coated balloons that are currently available, noting he is excited to get the products in hand to start with. He discusses an upcoming trial in Germany, the Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooN Angioplasty in the Femoropopliteal Artery, which will include almost 500 patients and evaluate 12-month primary patency. Dr. Scheinert further discusses the SIRONA trial design.

Dr. Sahil Parikh is excited to have this device in the USA. Concept Medical has received Breakthrough Device Designation for Magic Touch PTA with BTK indications. Dr. Sahil Parikh states that SCB is an unmet need in the USA.

Back to Top